GLP for weight loss refers to GLP-1 receptor agonist medications, a class of injectable drugs that mimic the gut hormone glucagon-like peptide-1. They slow stomach emptying, reduce appetite signals in the brain, and improve insulin response. Two are FDA-approved for chronic weight management: semaglutide (Wegovy) and tirzepatide (Zepbound). Average weight loss in major trials ranges from 15% to 22% of body weight over 68 to 72 weeks.
How GLP-1 Works in the Body
GLP-1 is a natural hormone secreted by L-cells in the small intestine within minutes of eating. It tells the pancreas to release insulin, tells the liver to stop dumping glucose into the blood, slows how quickly the stomach empties, and activates satiety centers in the hypothalamus. Native GLP-1 breaks down within minutes. Synthetic analogs are modified to resist that breakdown, so a single weekly injection keeps receptors active for days.
The FDA-Approved Options
| Drug | Molecule | Approved For | Average Weight Loss |
|---|---|---|---|
| Wegovy | Semaglutide 2.4 mg weekly | Chronic weight management | ~15% at 68 weeks |
| Zepbound | Tirzepatide up to 15 mg weekly | Chronic weight management, obstructive sleep apnea | ~21% at 72 weeks |
| Saxenda | Liraglutide 3 mg daily | Chronic weight management | ~6-8% at 56 weeks |
| Ozempic | Semaglutide 1-2 mg weekly | Type 2 diabetes (not weight loss) | ~6-10% observed |
| Mounjaro | Tirzepatide up to 15 mg weekly | Type 2 diabetes (not weight loss) | Similar to Zepbound |
What the Major Trials Show
The STEP 1 trial randomized 1,961 adults with obesity and no diabetes to semaglutide 2.4 mg or placebo, producing an average 14.9% weight loss at 68 weeks in the treatment arm versus 2.4% with placebo. SURMOUNT-1 tested tirzepatide in 2,539 similar adults; the 15 mg arm lost an average 20.9% of body weight at 72 weeks. Both trials also documented improvements in blood pressure, lipids, waist circumference, and prediabetes reversal rates.
Side Effects to Expect
Gastrointestinal symptoms dominate. The most common are:
- Nausea (affecting 30-45% of users, most in the first 8-12 weeks)
- Diarrhea or constipation
- Vomiting, especially after overeating
- Acid reflux or belching
- Fatigue and headaches during dose escalation
Less common but more serious risks include gallstones, pancreatitis, and a possible association with medullary thyroid cancer (seen in rodent studies; human data remain uncertain). The FDA maintains current safety alerts for each drug.
Who Qualifies for GLP Weight-Loss Therapy
Per labeling, Wegovy and Zepbound are approved for adults with:
- BMI 30 or higher (obesity), or
- BMI 27 or higher with at least one weight-related condition such as high blood pressure, dyslipidemia, obstructive sleep apnea, or type 2 diabetes
Wegovy is also approved for adolescents aged 12 and older with obesity. Neither is approved for cosmetic weight loss in people of normal weight.
GLP and Prediabetes
Weight loss of 5 to 10% reliably improves insulin sensitivity. The larger weight losses seen with GLP-1 drugs often move A1C out of the prediabetic range. A meta-analysis of SURMOUNT trials found that more than 90% of participants with prediabetes at baseline had normal glucose tolerance after 72 weeks of tirzepatide. However, lifestyle change remains the first-line treatment. For most people with prediabetes, GLP drugs are considered when BMI is 30 or higher or when multiple risk factors overlap. See our treatment hub and is prediabetes reversible for lifestyle-first strategies.
Cost and Access
List prices run roughly $1,000 to $1,400 per month in the US without insurance. Coverage varies widely; many commercial plans now cover obesity medications, but Medicare has historically excluded weight-loss drugs (though this is evolving). Manufacturer savings cards and patient-assistance programs can lower out-of-pocket costs for eligible patients. Compounded versions marketed online are not FDA-approved and carry real safety risks.
What Happens When You Stop
The STEP 4 and SURMOUNT-4 extension trials showed that stopping the medication leads to steady weight regain over one to two years. This reflects the underlying biology of obesity, which is a chronic condition. Plans to stop or taper should be discussed with a clinician and paired with structured lifestyle support.
The Bottom Line
GLP for weight loss is the most effective pharmacologic approach to obesity available today. Semaglutide and tirzepatide deliver 15% to 22% average body-weight reductions, along with improvements in blood pressure, lipids, and glucose. Side effects are common but usually manageable, and the medications work best as part of a long-term plan that includes nutrition, activity, and sleep. Whether GLP is right for you is a clinical decision, not a trending-product one.
Medical disclaimer: This article is for educational purposes and is not medical advice. Decisions about obesity medications should be made with a qualified clinician.
